

ASX Announcement

30 July 2025

Quarterly Report Webinar

11am (AEST) Tuesday 12 August 2025

ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to invite shareholders, investors and other interested parties to a webinar discussing the June 2025 quarterly report as well as recent developments for the Company.

The webinar will be hosted by CEO Julian Chick at **11am AEST on Tuesday 12 August 2025**.

To join the webinar, please register at the following link:

https://us02web.zoom.us/webinar/register/WN_8IV3I_3RDu7CtoN1APUHw

A recording will be available at the above link shortly after the conclusion of the live session.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – our bioabsorbable, eCOO-based protective wrap, naturally absorbed within six months of surgery.
- **NervAlign® Nerve Conduit** – next generation nerve conduit product range leveraging advantages of eCOO technology in a form designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Cap** – protective sheath designed to cap free nerve ends to prevent growth of painful neuromas.
- **NervAlign® Nerve Guide Matrix** – off-the-shelf, size customised nerve graft replacement, eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.96 billion in 2024 and projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)